Clinical Trials Update from NCI, November 9, 2016
|Updates from the National Cancer Institute|
|Clinical Trials News|
|COMET Study: Educating Patients about Genetic Test Results|
An Interview with Carol Weil about the COMET Study, an ancillary study of NCI-MATCH. Its purpose is to test whether educating participants about genetic testing will increase their knowledge and reduce their stress after they receive results of tumor profiling tests.
|Modified Immunotherapy Approach Shows Promise for Leukemia|
Results from an early clinical trial suggests that a new method of preparing immune cells may lead to a potential treatment option for some patients with acute myeloid leukemia (also known as AML).
|We Want to Hear from You!|
If you have ideas on how NCI can improve the clinical trials search form, we'd love to hear from you! Visit the feedback form on our clinical trials search page to share your ideas.
|Clinical Trials Information for Patients and Caregivers|
|Use of Placebos|
Placebos are rarely used in clinical trials of new cancer treatments. Learn about the limited role that placebos may play in some cancer clinical trials.
|Research Team Members|
Designing and running clinical trials require the skills of many different types of experts. Learn about the typical roles and responsibilities of clinical trial team members.
|Featured NCI-Supported Clinical Trials|
|Retinoblastoma Follow-Up Study|
The NCI Retinoblastoma Follow-up Study team is seeking people who took part in this study as children. The team is trying to reach patients who were diagnosed with retinoblastoma and treated in New York or Boston, especially between 1984 and 2006.
|Lung-MAP: Master Protocol for Squamous Cell Lung Cancer|
Lung-MAP is for patients with advanced squamous cell lung cancer that has not responded or has stopped responding to standard treatment. In this study, patients will be assigned to substudies based on genetic changes in their tumors.
| T-Cell Receptor Gene Therapy Targeting HPV-16-positive Cancers|
This phase 1 trial is for patients with HPV-16-positive cervical, vulvar, penile, anal, or oropharyngeal cancers that have spread, come back, or gotten worse after treatment. The purpose is to study the side effects and find the best dose of T-cell receptor gene therapy when given together with pembrolizumab.